EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of antiretroviral therapy on gut microbiota, immune activation, and inflammatory markers in newly diagnosed HIV patients

Denisse Márquez-Ruiz, Francisco Illanes-Álvarez, Andrés Martín-Aspas, Ismael Tinoco Racero, Irene Campaña-Gómez, Raquel Guerra-González, Alberto Romero-Palacios, Mercedes Márquez-Coello, Sara Cuesta-Sancho, José-Antonio Girón-González

Frontiers in Cellular and Infection Microbiology · 27.07.2026 · 16

DOI: 10.3389/fcimb.2026.1853799 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 27.07.2026. Verfasst von Denisse Márquez-Ruiz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Medicina Interna, Unidad de Enfermedades Infecciosas, Hospital Universitario Puerta del Mar, Cádiz, Spain. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, HIV Infections, Inflammation, Anti-Retroviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Consejería de Salud y Consumo, Junta de Andalucía, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

People living with HIV (PLWH) exhibit gut dysbiosis and chronic immune activation. The early dynamics of the gut-immune axis during the transition from diagnosis to viral suppression remain incompletely understood.

Methods

We characterized fecal microbiota (16S rRNA), bacterial translocation (16S rDNA) and gut barrier integrity (serum intestinal fatty acid-binding protein, I-FABP, level) in newly diagnosed PLWH at baseline (t0) and after six months of suppressive ART (t6), compared to uninfected controls. Systemic inflammation (serum concentrations of interleukins 6 and 10, soluble CD163), and peripheral blood T-cell activation were also analyzed.

Results

Alpha diversity was similar across groups (p>0.05); beta diversity differed significantly between PLWH at t0 and controls (p=0.002). Linear Discriminant Analysis Effect Size (LEfSe) analysis identified an enrichment of short chain fatty acids (SCFA)-producing genera ( Alloprevotella , Mitsuokella , Succinivibrio , Megasphaera ) in PLWH at t0. PLWH at t0 showed elevated bacterial translocation [16S rDNA, 4281 (4018-4485) vs 2162 (2023-2286) copies/mL, p<0.001], gut barrier damage [I-FABP, 950 (800-1168) vs 767 (574-902) ng/mL, p=0.012], inflammation [IL-6, 4.8 (3.1-8.8) vs 0.8 (0.3-1.3) pg/mL, p<0.001; sCD163, 1173 (872-1417) vs 561 (425-662) ng/mL, p<0.001], and T-cell activation [CD4 + CD38 + HLA-DR + (percentage of CD4 + T lymphocytes), 9.7 (2.8-18.5) vs 1.3 (0.3-2.2), p=0.007; CD8 + CD38 + HLA-DR + (percentage of CD8+T lymphocytes), 19.0 (12.0-31.1) vs 1.7 (0.6-5.7), p=0.005], compared with controls. Treated PLWH (t6) showed similar alpha and beta diversities of fecal microbiota compared to untreated PLWH (p>0.05 in each case). LEfSe analysis identified an enrichment of Campylobacter and Atopobium at t6. ART mitigates systemic inflammation [t6 vs t0, IL-6, 3.3 (1.7-4.0) vs 4.8 (3.1-8.8) pg/mL, p=0.022; sCD163, 795 (549-915) vs 1173 (872-1417) ng/mL, p<0.001], and T-cell activation [t6 vs t0, CD4 + CD38 + HLA-DR + (percentage of CD4 + T lymphocytes), 2.7 (1.7-6.3) vs 9.7 (2.8-18.5), p=0.047; CD8 + CD38 + HLA-DR + (percentage of CD8 + T lymphocytes), 6.5 (3.7-15.5) vs 19.0 (12.0-31.1), p=0.086].

Conclusions

Untreated PLWH show a dysbiotic signature, characterized by enrichment of SCFA-producers. Compared to controls, the fecal microbiota of PLWH after 6 months of ART (t6) continued to show differences characterized by a predominance of Alloprevotella and Succinivibrio , among others, and continued elevations in intestinal injury, bacterial translocation, and inflammatory/immune activation markers, underscoring the incomplete normalization of gut-immune homeostasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeHIV InfectionsInflammationAnti-Retroviral AgentsHumansMaleFemaleBacterial TranslocationFecesBiomarkersLymphocyte ActivationRNA, Ribosomal, 16SAdultDysbiosisAntigens, CDIntestinal Barrier FunctionDNA, RibosomalMiddle AgedBacteriaDNA, BacterialAntigens, Differentiation, MyelomonocyticCD163 AntigenFatty Acids, VolatileInterleukin-6

Stichwörter der Autor:innen

HIVantiretroviral therapygutimmune activationinflammationmicrobiota

Substanzen

BiomarkersRNA, Ribosomal, 16SAntigens, CDDNA, RibosomalDNA, BacterialAnti-Retroviral AgentsAntigens, Differentiation, MyelomonocyticCD163 AntigenFatty Acids, VolatileInterleukin-6

Autor:innen und Institutionen

  • Servicio de Medicina Interna, Unidad de Enfermedades Infecciosas, Hospital Universitario Puerta del Mar, Cádiz, Spain.
  • Instituto para la Investigación e Innovación Biomédica de Cádiz (INiBICA), Cádiz, Spain.
  • Facultad de Medicina, Universidad de Cádiz, Cádiz, Spain.
  • Unidad de Enfermedades Infecciosas, Facultad de Medicina, Hospital Universitario Puerto Real, Cádiz, Spain.
  • Mucosal Immunology Lab, Department of Paediatrics and Immunology, University of Valladolid, Institute of Biomedicine and Molecular Genetics (IBGM, University of Valladolid-CSIC), Valladolid, Spain.
  • Health Research Institute of Valladolid (IBioVALL), Valladolid, Spain.

Förderung

  • Consejería de Salud y Consumo, Junta de Andalucía
  • Instituto de Salud Carlos III

Zitieren

APA

Márquez-Ruiz, D., Illanes-Álvarez, F., Martín-Aspas, A., Tinoco Racero, I., Campaña-Gómez, I., Guerra-González, R., Romero-Palacios, A., Márquez-Coello, M., Cuesta-Sancho, S., & Girón-González, J. A. (2026). Effect of antiretroviral therapy on gut microbiota, immune activation, and inflammatory markers in newly diagnosed HIV patients. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1853799

Vancouver

Márquez-Ruiz D, Illanes-Álvarez F, Martín-Aspas A, Tinoco Racero I, Campaña-Gómez I, Guerra-González R, et al. Effect of antiretroviral therapy on gut microbiota, immune activation, and inflammatory markers in newly diagnosed HIV patients. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1853799

BibTeX
@article{MrquezRuiz2026,
  author = {Márquez-Ruiz, Denisse and Illanes-Álvarez, Francisco and Martín-Aspas, Andrés and Tinoco Racero, Ismael and Campaña-Gómez, Irene and Guerra-González, Raquel and Romero-Palacios, Alberto and Márquez-Coello, Mercedes and Cuesta-Sancho, Sara and Girón-González, José-Antonio},
  title = {Effect of antiretroviral therapy on gut microbiota, immune activation, and inflammatory markers in newly diagnosed HIV patients},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fcimb.2026.1853799}
}
Kostenlos starten →